GSK scores win for long-acting 2-drug HIV therapy by Angus Liu Wednesday, August 15, 2018 A cabotegravir/rilpivirine combo as a monthly HIV treatment showed similar efficacy to a standard three-drug therapy.
Truvada maker Gilead's new TV ad promotes healthy sex by Beth Snyder Bulik Wednesday, June 6, 2018 In Gilead's new TV awareness ads for HIV prevention, actors talk “honestly” about fearing HIV testing and having unprotected sex.
Gilead strikes at GSK with positive HIV head-to-head trial data by Arlene Weintraub Tuesday, March 6, 2018 Gilead released data from a clinical trial showing that its new three-med HIV combo Biktarvy is noninferior to a treatment containing three GSK drugs.
Gilead's Biktarvy eyes megablockbuster sales with FDA nod by Eric Sagonowsky Wednesday, February 7, 2018 After reporting a dismal hep C sales outlook, Gilead got a boost with an FDA nod for HIV combo Biktarvy, a drug with sales estimates of up to $10B.
Merck and ViiV are keeping their TV ads real. Who'll follow? by Carly Helfand Wednesday, December 20, 2017 Pharma is big on getting real patients to share their stories. Now, it’s starting to put those stories on the small screen.
ViiV starts 'Moving Forward' into first branded HIV TV ads by Beth Snyder Bulik Monday, December 4, 2017 ViiV Healthcare is taking its history in HIV treatment and community involvement to the small screen.
Post-Juluca nod, GSK beefs up trials of long-acting HIV duo by Carly Helfand Tuesday, November 28, 2017 GlaxoSmithKline’s ViiV only just won its first two-drug HIV approval, but it's already bolstering its trial program.
Glaxo turns up the heat on Gilead with landmark 2-drug HIV win by Carly Helfand Tuesday, November 21, 2017 GlaxoSmithKline’s two-drug HIV bet just paid off.
McCann Health taps veteran to lead HCP agency McCann Echo by Beth Snyder Bulik Wednesday, September 6, 2017 Healthcare professional ad agency McCann Echo has named Jesse Johanson president in a move that looks to the veteran to continue growing the agency.
Pharma mold-breaker Witty exits after 9 years at the GSK helm by Carly Helfand Friday, March 31, 2017 Andrew Witty's nine-year GSK CEO tenure saw him break with his peers—sometimes, to the tune of heavy criticism—more than once.
